報價延遲最少15分鐘:2026/09/04 08:43 EDT
盤前時段
|
||||
|
14.6 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.6
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.44/-8.16
|
|
企業價值
240.51M
|
| 資產負債 |
|
每股賬面淨值
12.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.76M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes. |
